Company intelligence / Profile preview

BIO3S Co., Ltd.

Gwangju, Jeollanam-do, South Koreabio3s.com ↗

Ownership: Private
Development stage: Other

Overview

BIO3S has developed virus diagnostic technologies and patented soybean-derived protein lectins with potential anti-coronavirus activity. The company collaborates with Chonnam National University and focuses on both diagnostics and novel biotherapeutics for infectious diseases. No published clinical trial results as of June 2025.

Therapeutic areas: Infectious Diseases
Modalities: Protein therapeutics (lectins)diagnostics technologies
Industry: Biotech

Partnerships

Chonnam National University – research collaboration/investment-type partnership for virus diagnostic technology development

Beyond the preview

Go deeper on BIO3S Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIO3S Co., Ltd..

Explore the full profile